The systemic exposure to inhaled beclometasone/formoterol pMDI with valved holding chamber is independent of age and body size

Conclusions The systemic exposure to the active ingredients of a fixed dose combination of beclometasone/formoterol administered via pMDI with AeroChamber Plus™ correlates with the nominal dose independently of patient age and body size. Thus, dose reduction in relation to age when using a pMDI with VHC may be unnecessary for reducing the systemic exposure in children.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research